EGFR and cancer: We conducted IC50 experiments with two distinct third‐generation TKI drugs, Almonertinib and Osimertinib, to demonstrate that exposing EGFR mutated cancer cell lines, such as HCC827, PC9 and NCI‐H1975 (T790M+ cell line) to conditioned medium (CM) from PCs resulted in reduced sensitivity to TKI treatment compared to cells exposed to CM from control cancer cells (Figures2A,B; Figures S2A,B, Supporting Information).